Freeman J, ALTIERI R, Freeman A, Kuo T, Sardinha F, Buckingham C
J Natl Med Assoc. 1994; 86(3):203-8.
PMID: 8189453
PMC: 2568182.
Eliopoulos G, Gardella A, Moellering Jr R
Antimicrob Agents Chemother. 1984; 25(3):331-5.
PMID: 6721464
PMC: 185510.
DOI: 10.1128/AAC.25.3.331.
Nakamura S, Minami A, Katae H, Inoue S, Yamagishi J, Takase Y
Antimicrob Agents Chemother. 1983; 23(5):641-8.
PMID: 6575721
PMC: 184780.
DOI: 10.1128/AAC.23.5.641.
Garcia I, Bodey G, Fainstein V, Ho D, LeBlanc B
Antimicrob Agents Chemother. 1984; 26(3):421-3.
PMID: 6508271
PMC: 176185.
DOI: 10.1128/AAC.26.3.421.
DARRELL R, Modak S, FOX Jr C
Trans Am Ophthalmol Soc. 1984; 82:75-91.
PMID: 6242083
PMC: 1298655.
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.
Haase D, Harding G, Thomson M, Kennedy J, Urias B, Ronald A
Antimicrob Agents Chemother. 1984; 26(4):481-4.
PMID: 6240223
PMC: 179948.
DOI: 10.1128/AAC.26.4.481.
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
Gay J, DeYoung D, Roberts G
Antimicrob Agents Chemother. 1984; 26(1):94-6.
PMID: 6236748
PMC: 179925.
DOI: 10.1128/AAC.26.1.94.
Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.
Cofsky R, duBouchet L, Landesman S
Antimicrob Agents Chemother. 1984; 26(1):110-1.
PMID: 6236745
PMC: 179930.
DOI: 10.1128/AAC.26.1.110.
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
Forward K, Harding G, Gray G, Urias B, Ronald A
Antimicrob Agents Chemother. 1983; 24(4):602-4.
PMID: 6228193
PMC: 185382.
DOI: 10.1128/AAC.24.4.602.
Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.
Shungu D, Tutlane V, GADEBUSCH H
J Clin Microbiol. 1983; 18(4):988-91.
PMID: 6226677
PMC: 270948.
DOI: 10.1128/jcm.18.4.988-991.1983.
In vitro and in vivo antibacterial activity of AT-2266.
Kouno K, Inoue M, Mitsuhashi S
Antimicrob Agents Chemother. 1983; 24(1):78-84.
PMID: 6226242
PMC: 185107.
DOI: 10.1128/AAC.24.1.78.
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M
Antimicrob Agents Chemother. 1983; 24(1):54-60.
PMID: 6226241
PMC: 185104.
DOI: 10.1128/AAC.24.1.54.
Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.
Guerra J, Falconi E, Palomino J, Benavente L, Antunez De Mayolo E
Eur J Clin Microbiol. 1983; 2(3):260-5.
PMID: 6224684
DOI: 10.1007/BF02029529.
Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
Eandi M, Viano I, DI NOLA F, Leone L, GENAZZANI E
Eur J Clin Microbiol. 1983; 2(3):253-9.
PMID: 6224683
DOI: 10.1007/BF02029528.
Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole.
Crider S, Colby S
Antimicrob Agents Chemother. 1985; 27(1):71-5.
PMID: 3920958
PMC: 176207.
DOI: 10.1128/AAC.27.1.71.
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Holmes B, Brogden R, Richards D
Drugs. 1985; 30(6):482-513.
PMID: 3908074
DOI: 10.2165/00003495-198530060-00003.
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.
Goldstein E, Alpert M, Ginsberg B
Antimicrob Agents Chemother. 1985; 27(3):422-3.
PMID: 3158277
PMC: 176290.
DOI: 10.1128/AAC.27.3.422.
Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.
Sabbaj J, Hoagland V, Shih W
Antimicrob Agents Chemother. 1985; 27(3):297-301.
PMID: 3158272
PMC: 176264.
DOI: 10.1128/AAC.27.3.297.
Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley L, Koornhof H
Antimicrob Agents Chemother. 1985; 28(2):331-42.
PMID: 2939797
PMC: 180242.
DOI: 10.1128/AAC.28.2.331.
Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
Qadri S, Johnson S
J Natl Med Assoc. 1989; 81(4):382-5.
PMID: 2738947
PMC: 2625981.